Compare GLU & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLU | SEER |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.8M | 97.3M |
| IPO Year | N/A | 2020 |
| Metric | GLU | SEER |
|---|---|---|
| Price | $19.12 | $1.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.1K | ★ 197.6K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | N/A | ★ 9.40 |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | ★ $16,578,000.00 |
| Revenue This Year | N/A | $2.14 |
| Revenue Next Year | N/A | $25.90 |
| P/E Ratio | $30.69 | ★ N/A |
| Revenue Growth | N/A | ★ 16.99 |
| 52 Week Low | $16.60 | $1.65 |
| 52 Week High | $21.69 | $2.41 |
| Indicator | GLU | SEER |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 38.38 |
| Support Level | $18.91 | $1.69 |
| Resistance Level | $20.17 | $1.96 |
| Average True Range (ATR) | 0.33 | 0.05 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 62.20 | 15.38 |
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.